Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.19 USD | +3.45% | -4.19% | -4.97% |
Jul. 01 | Akero Therapeutics, Inc.(NasdaqGS:AKRO) added to Russell Small Cap Comp Value Index | CI |
Jul. 01 | Akero Therapeutics, Inc.(NasdaqGS:AKRO) added to Russell 3000 Value Index | CI |
Chart calendar Akero Therapeutics, Inc.
Upcoming events on Akero Therapeutics, Inc.
Past events on Akero Therapeutics, Inc.
2024-06-07 12:00 pm | Annual General Meeting |
2024-06-05 04:00 pm | Jefferies Global Healthcare Conference |
2024-05-14 | BofA Securities Health Care Conference |
2024-05-10 07:00 am | Q1 2024 Earnings Release |
2024-03-04 08:00 am | Efruxifermin Phase 2b HARMONY Study Results Call |
2024-02-29 07:00 am | Q4 2023 Earnings Release |
2024-01-08 12:45 pm | JPMorgan Healthcare Conference |
2023-11-29 07:30 am | Evercore ISI HealthCONx Conference - Fireside Chat |
2023-11-15 12:00 pm | Jefferies London Healthcare Conference - Fireside Chat |
2023-11-13 03:15 pm | American Association for the Study of Liver Diseases Conference - Abstract Number: 5005 |
2023-11-13 01:00 pm | American Association for the Study of Liver Diseases Conference - Abstract Number: 48626 |
2023-11-13 07:00 am | Q3 2023 Earnings Release |
2023-10-24 12:00 pm | H.C. Wainwright NASH Investor Conference |
2023-10-10 08:00 am | Efruxifermin Phase 2b SYMMETRY Study Results Call |
2023-09-13 09:00 am | H.C. Wainwright Global Investment Conference |
2023-09-12 04:55 pm | Morgan Stanley Global Healthcare Conference |
2023-08-11 06:00 am | Q2 2023 Earnings Release |
2023-06-23 09:00 am | Annual General Meeting |
2023-06-07 10:30 am | Jefferies Global Healthcare Conference |
2023-06-05 08:00 am | SYMMETRY Cohort D Phase 2b Trial Results Call |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
EBITDA Million USD | Released Forecast Spread | -45,7 -45,4 -0.58% | -74,1 -67,6 -9.59% | -101 -97,0 -3.96% | -115 -123 6.44% | -173 -156 -10.52% | -257 |
EBIT Million USD | Released Forecast Spread | -45,7 -45,2 -0.96% | -80,2 -70,2 -14.17% | -101 -96,9 -4.15% | -115 -125 8.11% | -173 -160 -7.93% | -254 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -43,8 -45,1 2.98% | -79,2 -69,2 -14.42% | -101 -96,8 -4.11% | -112 -125 10.33% | -152 -148 -2.85% | -243 |
Net income Million USD | Released Forecast Spread | -43,8 -45,6 4.11% | -79,2 -68,6 -15.46% | -101 -96,5 -4.47% | -112 -125 10.04% | -152 -147 -3.3% | -240 |
EPS USD | Released Forecast Spread | -2,90 -2,83 -2.41% | -2,52 -2,20 -14.49% | -2,89 -2,76 -4.88% | -2,87 -3,22 10.73% | -2,89 -2,90 0.24% | -3,83 |
Announcement Date | 16/03/20 | 16/03/21 | 25/02/22 | 17/03/23 | 29/02/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | ||
EBITDA Million USD | Released Forecast Spread | -26,0 -29,0 10.21% | -27,6 | -36,1 -32,0 -12.75% | -25,4 -37,0 31.32% | -28,7 -28,0 -2.65% | -35,6 -33,0 -7.93% | -46,6 -40,0 -16.53% | -61,9 -43,0 -43.89% | -60,0 -66,0 9.16% | -65,0 | -71,0 | -77,0 | ||
EBIT Million USD | Released Forecast Spread | -26,1 -28,2 7.76% | -27,6 -33,8 18.35% | -36,1 -30,4 -18.82% | -25,4 -35,9 29.15% | -28,8 -29,8 3.61% | -35,6 -32,1 -10.83% | -46,6 -37,0 -25.97% | -61,9 -48,3 -28.07% | -60,0 -57,9 -3.61% | -61,4 | -63,9 | -71,6 | -67,6 | -70,0 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -26,0 -29,3 11.02% | -27,4 -33,8 18.9% | -35,5 -30,8 -15.29% | -23,1 -36,0 35.87% | -25,8 -30,0 13.85% | -31,1 -32,2 3.52% | -39,7 -36,0 -10.14% | -55,2 -48,0 -14.98% | -53,3 -54,5 2.21% | -57,2 | -60,8 | -72,5 | ||
Net income Million USD | Released Forecast Spread | -26,0 -28,2 7.83% | -27,4 -33,8 18.9% | -35,5 -30,3 -17.22% | -23,1 -35,6 35.3% | -25,8 -29,6 12.81% | -31,1 -32,2 3.52% | -39,7 -37,1 -6.77% | -55,2 -48,5 -13.89% | -53,3 -54,6 2.23% | -57,4 | -60,0 | -67,5 | -68,9 | -71,2 |
EPS USD | Released Forecast Spread | -0,74 -0,81 8.51% | -0,77 -0,90 14.58% | -0,92 -0,72 -27.83% | -0,49 -0,80 38.44% | -0,55 -0,67 18.15% | -0,60 -0,70 13.67% | -0,71 -0,68 -4.55% | -0,99 -0,87 -13.86% | -0,90 -0,95 5.51% | -0,89 | -0,93 | -1,04 | -1,21 | -1,06 |
Announcement Date | 06/05/22 | 05/08/22 | 04/11/22 | 17/03/23 | 15/05/23 | 11/08/23 | 13/11/23 | 29/02/24 | 10/05/24 | - | - | - | - | - |
Past sector events for Akero Therapeutics, Inc.
2024-06-05 03:51 am | PHARMAESSENTIA CORPORATION: May 2024 Sales and Revenue Release |
2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
2024-05-16 07:46 am | BIOCON LIMITED: Q4 2024 Earnings Release |
2024-05-16 01:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
2024-05-15 | LIGACHEM BIOSCIENCES INC.: Q1 2024 Earnings Release |
2024-05-15 08:05 am | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
2024-05-15 07:00 am | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
2024-05-14 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
2024-05-14 04:05 pm | ENLIVEN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 04:00 pm | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- AKRO Stock
- Calendar Akero Therapeutics, Inc.